About Boehringer Ingelheim
Boehringer Ingelheim news and updates
Boehringer Ingelheim Pharmaceuticals, Inc. is developing novel monoclonal antibodies for potential canine therapeutic treatments
Boehringer Ingelheim, a global leader in animal health, and MabGenesis, a private biopharmaceutical company headquartered in Yokohama, Japan, announce that they have entered into a collaboration to discover and develop novel monoclonal antibodies for potential canine therapeutic treatments.
Jan 1, 2022 | boehringer-ingelheim.comGilbert left Boehringer Ingelheim GmbH as associate director of compliance on Jan 1st 18'.
Gilbert comes to the Maryland-based company from Boehringer Ingelheim, where she had been associate director of compliance since 2018.
Jan 1, 2022 | radicalcompliance.comKaren left Boehringer Ingelheim GmbH as Vice President, Total Rewards U.S. on Jan 22nd 22'.
Karen joins CWT from Boehringer Ingelheim, where she had a 20+ year career in various HR roles, most recently as Vice President, Total Rewards U.S., where she led the attraction, retention, and orientation strategy for the business, with responsibilities spanning compensation and mobility services, health and welfare benefits, fleet management services, and change and project management.
Jan 1, 2022 | hospitalitynet.orgBob retires from Boehringer Ingelheim GmbH
Bob retired from Boehringer Ingelheim as a pharmaceutical sales representative.
Jan 1, 2022 | beaconjournal.comBoehringer Ingelheim GmbH recognized as Top Employer in Australia & New Zealand
In addition to being certified at the global level, Boehringer Ingelheim has been named as a Top Employer in Australia & New Zealand for the second consecutive year, as well as across the region in ASEAN and Korea - with over 2,700 employees from 24 different nationalities.
Jan 1, 2022 | asiaone.comBoehringer Ingelheim GmbH recognized as Top Employer in Philippines
Besides being certified at the global level, Boehringer Ingelheim has also been named as a Top Employer in Philippines for the fourth consecutive year, as well as across the region in ASEAN, Korea, Australia & New Zealand - with over 2,700 employees from 24 different nationalities.
Jan 1, 2022 | asiaone.comBoehringer Ingelheim GmbH recognized as Global Top Employer on Jan 1st 22'.
For the second time running, Boehringer Ingelheim has been named a Global Top Employer – one of only 11 companies that has been awarded this title for 2022.
Jan 1, 2022 | channelnewsasia.comBoehringer Ingelheim GmbH recognized as top 11 employers worldwide
Based on human resources and employee-centric practices, Takeda and Boehringer Ingelheim are among the top 11 employers worldwide.
Jan 1, 2022 | europeanpharmaceuticalreview.comEvotec AG partnered with Boehringer Ingelheim GmbH on Jan 25th 22'.
(RTTNews) - Evotec AG (EVTCY.PK), a German drug discovery and development company, Tuesday said it has entered into a target and drug discovery partnership with Boehringer Ingelheim in ophthalmology.
Jan 1, 2022 | nasdaq.comBearingPoint partners with Boehringer Ingelheim GmbH
Management and technology consultancy BearingPoint worked with Boehringer Ingelheim in gathering data from each manual step involved in the storage process by using UiPath’s Task Capture®.
Jan 1, 2021 | chemanager-online.comIllumina, Inc. partnered with Boehringer Ingelheim GmbH on Jan 10th 22'.
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline.
Jan 1, 2022 | illumina.comYale Computer Graphics Group partnered with Boehringer Ingelheim GmbH on May 10th 21'.
Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world.
Jan 1, 2021 | indianconventions.comBoehringer Ingelheim GmbH partnered with Healx on Dec 1st 20'.
In December, Boehringer partnered with UK-based drug technology firm Healx to use AI for identifying approaches to treat rare neurological disorders.
Jan 1, 2020 | pharmaceutical-technology.comBoehringer Ingelheim GmbH partnered with Google Ventures on Jan 21st 21'.
Last year, Boehringer Ingelheim announced collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations.
Jan 1, 2022 | biopharmatrend.comFold partners with Boehringer Ingelheim GmbH
The open access project Fold.it teamed up with Boehringer Ingelheim to support the small molecule design efforts in DrugIt.
Jan 1, 2022 | opnme.comLifebit Biotech Ltd partnered with Boehringer Ingelheim GmbH on Jun 9th 21'.
London, United Kingdom, June 9, 2021 – Lifebit Biotech Ltd announces the beginning of a long-term partnership with Boehringer Ingelheim to utilise Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources.
Jan 1, 2021 | lifebit.websiteBoehringer Ingelheim GmbH launched Pradaxa on Oct 1st 10'.
In October 2010, Boehringer Ingelheim launched Pradaxa, and marketed this drug as the first new blood thinning treatment alternative to Warfarin (Coumadin) in over 50 years.
Jan 1, 2018 | masstortfirm.comBoehringer Ingelheim GmbH launched reusable Respimat on Dec 20th 21'.
Boehringer Ingelheim, for example, has recently launched their new reusable Respimat which has a 71% smaller carbon footprint after 6 months of use compared to their disposable version [1] (Figure 1).
Jan 1, 2022 | springboard.proBoehringer Ingelheim GmbH launched Centragard on Aug 1st 17'.
For instance, in August 2017, Boehringer Ingelheim launched Centragard, a transdermal solution for the treatment and control of three of the most common intestinal parasites of cats such as hookworms, roundworms, and tapeworms.
Jan 1, 2022 | einnews.comBoehringer Ingelheim GmbH launched swine vaccine Ingelvac PRRS MLV on Jan 1st 19'.
For instance, in January 2019, Boehringer Ingelheim launched swine vaccine Ingelvac PRRS MLV in China.
Jan 1, 2021 | medgadget.comBoehringer Ingelheim GmbH signs new client U.S. Department of Agriculture has explained
The U.S. Department of Agriculture has selected Boehringer Ingelheim to continue supplying antigen for a vaccine bank that protects U.S. livestock from a potential outbreak of foot-and-mouth disease (FMD).
Jan 1, 2021 | pig333.comBoehringer Ingelheim GmbH sold assets to Centrexion Therapeutics Corp. on Jan 1st 16'.
According to Centrexion, CNTX-4975 has been shown in clinical studies to provide significant and durable relief from localized moderate to severe knee OA pain by the second day Centrexion acquired CNTX-02902 and two other pain candidates from Boehringer Ingelheim in March 2016 for an undisclosed price.
Jan 1, 2019 | genengnews.comBoehringer Ingelheim GmbH is developing companion diagnostics for oncology products
Illumina and Boehringer Ingelheim have collaborated to develop companion diagnostics for oncology products.
Jan 1, 2022 | nsmedicaldevices.comDomain Therapeutics partnered with Boehringer Ingelheim GmbH on Dec 4th 18'.
Strasbourg, France, December 4, 2018 – Domain Therapeutics announces a multi-target drug discovery collaboration and licensing agreement with Boehringer Ingelheim on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.
Jan 1, 2018 | domaintherapeutics.caArtiQ partnered with Boehringer Ingelheim GmbH on Feb 4th 22'.
Recently the ArtiQ team joined forces with Boehringer Ingelheim, a global leader in providing pharmaceutical solutions for patients with IPF among other lung diseases.
Jan 1, 2022 | artiq.euExosome partners with Boehringer Ingelheim GmbH
Joana Correia, CEO of Exogenus Therapeutics emphasized “Exosome is delighted to partner with Boehringer Ingelheim in this endeavor, in the hope of unlocking new options for more patients with unmet needs.
Jan 1, 2022 | exosome-rna.comBioInformant Worldwide, LLC partners with Boehringer Ingelheim GmbH
Joana Correia, CEO of Exogenus Therapeutics emphasized “BioInformant Worldwide, LLC is delighted to partner with Boehringer Ingelheim in this endeavor, in the hope of unlocking new options for more patients with unmet needs.
Jan 1, 2022 | bioinformant.comBoehringer Ingelheim GmbH sells assets to Indical
Indical has acquired the Svanova product portfolio from Boehringer Ingelheim.
Jan 1, 2021 | fideliocapital.seSaniona partnered with Boehringer Ingelheim GmbH on Jan 1st 20'.
Erichsen started her career at NeuroSearch, before the company’s well-documented problems drove her to Saniona, which is itself now partnered with Boehringer.
Jan 1, 2022 | fiercebiotech.comBoehringer Ingelheim GmbH partnered with PetMedix™ on Jan 12th 21'.
Boehringer Ingelheim has entered into a partnership with PetMedix, a UK based research and development stage biopharmaceutical company.
Jan 1, 2021 | petmedix.comBoehringer Ingelheim GmbH launched Jardiance phase III EMPA-KIDNEY trial on Mar 16th 22'.
In the latest news issued just yesterday, Boehringer Ingelheim announced its Jardiance ® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease.
Jan 1, 2022 | bioct.orgBoehringer Ingelheim GmbH is developing Locked Nucleic Acid on Dec 1st 17'.
For instance, in December 2017, Boehringer Ingelheim announced the partnership with Roche to develop oral novel Locked Nucleic Acid (LNA) oligonucleotides used to treat inflammatory bowel diseases (IBDs).
Jan 1, 2022 | prnewswire.comBoehringer Ingelheim GmbH launches swine industry's first porcine circovirus Type 2d-based baculovirus vector vaccine
To stay ahead on porcine circovirus associated disease management, Boehringer Ingelheim has launched the swine industry's first porcine circovirus Type 2d-based baculovirus vector vaccine.
Jan 1, 2022 | nationalhogfarmer.comBoehringer Ingelheim GmbH partnered with Lifebit on Mar 1st 22'.
In March, German colossus Boehringer Ingelheim teamed up with UK precision medicine software company Lifebit to build a platform that processes anonymized clinical data to accelerate drug discovery.
Jan 1, 2021 | labiotech.euBoehringer Ingelheim GmbH partnered with Cdr Life on May 1st 20'.
Similarly, in May 2020, Boehringer Ingelheim had collaborated with CDR-Life to develop antibody fragment-based therapeutics for GA.
Jan 1, 2022 | pharmacompass.comBoehringer Ingelheim GmbH invests into assets : pipeline in the amount of $27B
Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests healthy sales revenue from Eli Lilly-partnered SGLT2 inhibitor Jardiance.
Jan 1, 2022 | pharmaphorum.comTennessee files suit against Boehringer Ingelheim GmbH
A man from Tennessee has filed a lawsuit against Boehringer Ingelheim Pharmaceuticals, Inc., the maker of Pradaxa.
Jan 1, 2012 | philadelphiamedicalmalpracticelawyerblog.comBoehringer Ingelheim GmbH is developing Jardiance on Dec 1st 20'.
AZ’s big rivals Eli Lilly and Boehringer Ingelheim are also attempting to develop their class competitor Jardiance (empagliflozin) to prevent heart failure, but s uffered a setback in December when the drug failed to improve exercise ability in two phase 3 studies.
Jan 1, 2020 | pharmaphorum.comBoehringer Ingelheim GmbH recognized as Limited Memory, Product or Service – Large Company category
BCW and Boehringer Ingelheim were honored in the Limited Memory, Product or Service – Large Company category.
Jan 1, 2019 | businesswire.comBoehringer Ingelheim GmbH partnered with MD Anderson Cancer Center on Aug 12th 19'.
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center (link is external) today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers.
Jan 1, 2021 | boehringer-ingelheim.comRhonda retired from Boehringer Ingelheim GmbH on Jan 1st 15'.
Rhonda retired from Boehringer Ingelheim in 2015.
Jan 1, 2022 | newspressnow.comBoehringer Ingelheim GmbH launches upgraded version of Nexgard; Nexgard Spectra
Lately, Boehringer Ingelheim, the manufacturer of Nexgard had introduced an upgraded version of Nexgard; Nexgard Spectra, that offered more protection as compared to the previous version.
Jan 1, 2022 | improvepetcare.comBoehringer Ingelheim GmbH expands facilities to Athens, Georgia, United States
Boehringer Ingelheim announced that it will invest $57 million to expand its Animal Health Global Innovation Center in Athens, Georgia.
Jan 1, 2022 | biospace.comBoehringer Ingelheim GmbH increases headcount by 55
Germany-based pharmaceutical company Boehringer Ingelheim will create 55 jobs at its Animal Health Global Innovation Center in Athens, GA.
Jan 1, 2022 | businessfacilities.comCeleris AG partners with Boehringer Ingelheim GmbH
"Celeris AG is thrilled to have entered this collaboration with Boehringer Ingelheim.
Jan 1, 2022 | biospace.comEquine Network LLC partners with Boehringer Ingelheim GmbH
In conjunction with Horse Week, the Equine Network and Boehringer Ingelheim are happy to announce the Horse Week Film Contest.
Jan 1, 2021 | nwhorsesource.comBoehringer Ingelheim GmbH is developing Jardiance
Eli Lilly ( LLY ) and Boehringer Ingelheim are developing their diabetes medication Jardiance to target CKD.
Jan 1, 2022 | seekingalpha.comBoehringer Ingelheim GmbH launches Horse Week Film Contest
In conjunction with Horse Week, the Equine Network and Boehringer Ingelheim are happy to announce the Horse Week Film Contest.
Jan 1, 2022 | equisearch.comBoehringer Ingelheim GmbH launches Phase II data for BI 1015550
Boehringer Ingelheim has announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor.
Jan 1, 2022 | europeanpharmaceuticalreview.comBoehringer Ingelheim GmbH launches TwistPak
Boehringer Ingelheim, a global leader in animal health, announces its latest innovation: TwistPak ®, a revolutionary mixing platform.
Jan 1, 2022 | pig333.comProxygen partnered with Boehringer Ingelheim GmbH on Jun 3rd 20'.
The collaboration is the second for Proxygen, which announced a similar deal with Boehringer Ingelheim in late 2020.
Jan 1, 2020 | fiercebiotech.comBoehringer Ingelheim GmbH partnered with Vant on Apr 3rd 22'.
Two months ago, Boehringer Ingelheim teamed up with VantAI to identify potential protein degrading molecules for those “undruggable” targets, as well.
Jan 1, 2022 | biospace.comQuantify Research partners with Boehringer Ingelheim GmbH
Quantify has started a European RWE collaboration with Boehringer Ingelheim to conduct studies in heart failure in four countries across Europe.
Jan 1, 2022 | quantifyresearch.comBoehringer Ingelheim GmbH partners with Trutinobio
Cytokines […] Boehringer Ingelheim has struck a deal with Trutino Biosciences to develop three cytokine therapies.
Jan 1, 2020 | trutinobio.comQognify Ltd. partners with Boehringer Ingelheim GmbH
Qognify, a provider of video and Enterprise Incident Management (EIM) solutions announced a global Video Management System (VMS) roll-out project with the research-driven biopharmaceutical company - Boehringer Ingelheim.
Jan 1, 2022 | sourcesecurity.comBoehringer Ingelheim GmbH partnered with Constantia on Jun 4th 19'.
Boehringer Ingelheim has signed a deal with Constantia Flexibles to provide veterinarians and horse owners with an augmented reality packaging solution.
Jan 1, 2019 | informa.comBoehringer Ingelheim GmbH acquired Trutinobio on Jun 14th 22'.
Boehringer Ingelheim signed an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company.
Jan 1, 2022 | finsmes.comBoehringer Ingelheim GmbH will partner with Herning2022 on Aug 14th 22'.
Boehringer Ingelheim, a global pharmaceutical company and the world's largest equine medicine company, has joined forces with Herning2022 to promote equine health and veterinary training during the ECCO FEI World Championships in Herning Denmark from 6 to 14 August 2022.
Jan 1, 2022 | herning2022.comBoehringer Ingelheim GmbH partners with Seqster PDM, Inc.
Boehringer Ingelheim's long-term agreement with Seqster secures their leadership position for RWE initiatives across therapeutic areas.
Jan 1, 2022 | asianhhm.comQuantro Tx partners with Boehringer Ingelheim GmbH
Quantro Therapeutics has announced that it has entered a three-year collaboration, option and licence agreement with Boehringer Ingelheim for the identification and development of inhibitors for up to three cancer-associated transcription factors.
Jan 1, 2022 | pharmatimes.comBoehringer Ingelheim GmbH sells assets to Sanofi Genzyme
After Sanofi acquired the antacid from its original developer Boehringer Ingelheim in a 2017 asset swap, the company pulled the med from the U.S. market in 2019.
Jan 1, 2022 | fiercepharma.comBoehringer Ingelheim GmbH launched Phase III data from the InPedILD trial on Sep 6th 22'.
INGELHEIM, Germany & RIDGEFIELD, Conn.--( BUSINESS WIRE )--Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
Sep 5, 2022 | businesswirechina.comGenentech partnered with Boehringer Ingelheim GmbH on Jan 1st 83'.
In 1983, Genentech entered into a co-promotion agreement with Boehringer Ingelheim Pharmaceuticals, Inc. regarding the commercialization of human tissue-type plasminogen activator (t-PA) 1.
Sep 4, 2022 | gene.comBoehringer Ingelheim GmbH launched HVT vector vaccine on Jan 1st 06'.
HVT stands for Herpes Virus of Turkey and has been indeed a game-changer for the industry since 2006 when Boehringer Ingelheim launched the first HVT vector vaccine.
Sep 13, 2022 | wattagnet.comQxpshop partners with Boehringer Ingelheim GmbH
“QxP is proud to partner with Boehringer Ingelheim, a leading research-driven biopharmaceutical company.
Sep 20, 2022 | virtuosivr.comBoehringer Ingelheim GmbH launches Frontline Wormer
Boehringer Ingelheim launches Frontline Wormer, which will tackle intestinal worms alongside its range of flea and tick treatments.
Sep 20, 2022 | vettimes.co.ukBoehringer Ingelheim GmbH is developing SZN-413 and other Fzd4-specific Wnt-modulating molecules
Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including as a treatment for retinal diseases, in exchange for an upfront payment to Surrozen of $12.5 million.
Oct 5, 2022 | surrozen.comAmerican College of Cardiology partners with Boehringer Ingelheim GmbH
The American College of Cardiology, in collaboration with Boehringer Ingelheim and Eli Lilly and Company (Lilly), is launching an initiative to educate cardiologists who are familiar with the drug evidence for the use of the heart failure (HF) drug class SGLT2 inhibitors but would benefit from education on how to safely and effectively use them to treat patients.
Oct 3, 2022 | acc.orgUniversity of Texas partnered with Boehringer Ingelheim GmbH on Oct 13th 22'.
The University of Texas at Arlington has partnered with Boehringer Ingelheim to host the Innovation Prize Competition, a networking event and pitch competition for emerging life-science companies and bio-entrepreneurs to be held Oct. 13 at Pegasus Park in Dallas.
Oct 10, 2022 | uta.eduBoehringer Ingelheim GmbH launches AI and data science fellowship program for top talents
University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world.
Oct 19, 2022 | topionetworks.comMerial merges with Boehringer Ingelheim GmbH
Merial, which merged with Boehringer Ingelheim in 2017, reported Aug. 21 that the U.S. Food and Drug Administration accepted the company’s findings from two laboratory studies.
Aug 22, 2018 | todaysveterinarybusiness.comBoehringer Ingelheim GmbH will launch SoundTalks on Nov 2nd 22'.
Boehringer Ingelheim has launched SoundTalks, which uses algorithms and artificial intelligence combined with always-on, in-barn audio monitoring to help swine producers detect and respond to respiratory disease up to 5 days earlier than conventional methods, leading to earlier treatment and recovery, resulting in improved productivity and reduced costs.
Oct 28, 2022 | pigprogress.netBoehringer Ingelheim GmbH partners with Vision Health Specialties LLP
Boehringer Ingelheim will cooperate with VisionHealth on improving the use of its ‘Kata’ app, which provides therapy support for asthma and chronic obstructive pulmonary disease (COPD).
Jul 12, 2022 | pharmatimes.comBoehringer Ingelheim GmbH is developing CT-155
For instance, Boehringer Ingelheim, in particular, has collaborated with Click Therapeutics, to develop and commercialise CT-155, a novel prescription digital therapeutic to aid in the treatment of schizophrenia.
Nov 22, 2022 | expresspharma.inHealx partnered with Boehringer Ingelheim GmbH on Dec 9th 19'.
UK, AI-powered biotech Healx is joining forces with Boehringer Ingelheim to identify indications related to rare neurological diseases.
Dec 9, 2019 | pharmatimes.comOgilvy Brisbane partnered with Boehringer Ingelheim GmbH on Oct 29th 22'.
Ogilvy Network ANZ has significantly expanded its relationship with Boehringer Ingelheim (BI), recently winning work for its Livestock Division in a competitive pitch.
Nov 28, 2022 | lbbonline.comBoehringer Ingelheim GmbH launches PRRS Knowledge Manual
Boehringer Ingelheim has launched the PRRS Knowledge Manual, a handbook chronicling 25+ years of porcine reproductive and respiratory syndrome virus (PRRSV) research and best practices for control, as well as a comprehensive overview of the history of PRRSV, its immunology, and practical advice for prevention and control.
Nov 30, 2022 | pigprogress.netBoehringer Ingelheim GmbH is developing novel therapies based on Ribon’s CD38 program
Boehringer Ingelheim aims to develop novel therapies based on Ribon’s CD38 program to transform the lives of patients with immunological and fibrotic diseases.
Nov 29, 2022 | pharmafocusasia.comBoehringer Ingelheim GmbH receives award Innovation Passport
Boehringer Ingelheim announces that investigational compound BI 907828 has received the Innovation Passport from the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of de-differentiated liposarcoma (DDLPS).
Dec 6, 2022 | pharmiweb.comPfizer, Inc. partners with Boehringer Ingelheim GmbH
US pharma company Pfizer (PFE: NYSE) and German pharma company Boehringer Ingelheim also benefit from the ruling.
Dec 7, 2022 | sharesmagazine.co.ukTorrent Pharmaceuticals Limited partners with Boehringer Ingelheim GmbH
Torrent Pharmaceuticals has partnered with Boehringer Ingelheim for co-markerting of diabetes and other cardiovascular medicines.
Dec 15, 2022 | tentaran.comBoehringer Ingelheim GmbH hired Vani Manja as Country Managing Director for India on Jan 1st 21'.
Boehringer Ingelheim has announced that Vani Manja is appointed Country Managing Director for India, effective January 1, 2021.
Jan 10, 2021 | boehringer-ingelheim.comBoehringer Ingelheim GmbH receives award Heinrich Wieland Prize
Ingelheim and Munich/Germany, 03 November 2006 - Prof. Alois Fuerstner from the Max-Planck-Institute for Coal Research in Muelheim/Ruhr received this year’s Heinrich Wieland Prize for exceptional achievements in the synthesis of glycolipids.
Nov 2, 2022 | heinrich-wieland-prize.deOccuity partners with Boehringer Ingelheim GmbH
Occuity has announced the signing of a preliminary agreement with research-driven pharmaceutical company, Boehringer Ingelheim, to enter their start-up acceleration programme.
Dec 18, 2022 | htworld.co.ukBoehringer Ingelheim GmbH is developing prescription digital therapeutic for patients with schizophrenia
Pharma company Boehringer Ingelheim and Click Therapeutics announced an expanded partnership to develop and commercialize another prescription digital therapeutic for patients with schizophrenia.
Dec 19, 2022 | mobihealthnews.comBoehringer Ingelheim GmbH hired Paola Casarosa as Board of Managing Directors on Dec 20th 22'.
INGELHEIM AM RHEIN, Germany--( BUSINESS WIRE )--Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors.
Dec 20, 2022 | businesswire.comBoehringer Ingelheim GmbH hired Paola as Global Head of Therapeutic Areas in the Human Pharma Business Unit on Jan 1st 07'.
Paola joined Boehringer Ingelheim in 2007 and is currently Global Head of Therapeutic Areas in the Human Pharma Business Unit.
Dec 20, 2022 | thepharmadata.com